Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Non-Comparative Phase 1/2 Study of NUV-422 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (HR+HER2-) Advanced Breast Cancer (aBC)

NCT05191004 is registered in ClinicalTrials.gov with Nuvation Bio Inc. as lead sponsor.

NCT NCT05191004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05191004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Non-Comparative Phase 1/2 Study of NUV-422 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (HR+HER2-) Advanced Breast Cancer (aBC)
Lead sponsor
Nuvation Bio Inc.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
September 30, 2022
Completion date
September 30, 2026
Enrollment
0 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer, breast carcinoma, breast tumor, cancer of breast, cancer of the breast, malignant tumor of breast, metastatic breast cancer